In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
CBDs seen to be a readily available and benign treatment for inflammation of many types. They may prove to be a treatment much easier on the body than the current course of drugs.
Create a database that tracks the long-term outcomes for patients on biologic medications (Remicade, Humira, Cimzia, Simponi, Tysabri, and Entyvio) to assess their long-term efficacy.
As IBD research and treatments progress, biologics are becoming an ever-more staple part of a patients treatment regimen. However, many patients still fail to respond effectively to these medications while others can maintain long-term remission specifically because of them. I believe it is important for the IBD community to further explore why this variation in response occurs, and tracking those that respond effectively to these biologic drugs can, perhaps, help us to better understand why some respond while others do not.
Multiple doctors have recommended that I start treatment for my Crohn's disease. There are many options from diet change, steroids, and immonosuapresants. My CD is very active and I have already had two surgeries.
After treatment failure with an anti-TNFa biologic medication (eg. Remicade, Humira), should patients attempt alternative anti-TNFa biologics or with biologic medications with different mechanisms?
Many patients experience diminished efficacy or complete loss of efficacy with anti-TNFa biologics. Which subsequent biologic medication option is most effective and safe?
I would like more research done on using the combination of a biologic (Humira) and Azathioprine (Imuran) together for treatment of crohns. Are the benefits really worth the risk? or is the risk not that bad?
I am on both of these meds and I have been questioned by my pharmacist about taking both of them together. I have read about the risks, and I'm not sure if I really do need both of the drugs. The information I have read seems to imply that getting cancer at some point is almost a certainty.
What pain treatment options (pharmacologic or otherwise) do IBD patients find most effective, and what are the risks associated with these treatments.
Many pain medications are addictive and/or harmful, particularly in IBD patients. Pain is a common symptom of IBD. I would like to explore patient experiences of the efficacy of pain treatments including: acupunctue, message therapy, heat therapy, NSAIDs, acetaminophen, SNRI antidepressants, tramadol, opiate pain medications. Either through literature review or additional research, it would be valuable to see a comprehensive review of risks and benefits of common pain treatments specific to use in IBD patients.
Is there a correlation between the use of NSAIDS (Ibuprofen) or other medications known to cause a "leaky gut" and the onset/development of IBD?
I took a large amount of Ibuprofen throughout my teen years for migraines. I have been told that taking Ibuprofen now can cause me to come out of remission due to causing a leaky gut and so I am curious to see if these types of medications can cause or trigger the onset of IBD in adolescents or in patient who chronically take these forms of medications.
What is unique about the histology and/or immunology of fistulas that limit their response to current immunomodulator therapies?
None of the currently approved or clinical stage immunotherapies for IBD have shown to offer substantive benefits in the improvement or healing of fistulas. This is continues to be a significant gap in the non-surgical treatment of fistulizing disease.
Do changes in manufacturing processes of Biologics alter the clinical impact (treatment success and/or adverse events)?
Biologic medications are developed through a complex process of using living organisms to harvest the biologic proteins. Manufacturers sometimes alter the manufacturing process, and these changes have the potential to cause slight changes in the final product. There is a lack of data/research regarding the impact of these slight changes. Furthermore, biosimilars (biologics developed by new manufacturers with different manufacturing processes), are pending FDA approval. Biosimilars will not require as extensive clinical testing prior to approval, compared with the original manufactured products. We ought to collect extensive data to better understand if slight changes in biologic proteins have a clinical impact.
There is a significant population of patients for whom biologics are no longer a viable or recommended treatment. Our healthcare going forward is complicated by the permanent effects of these medications on the body's systems.
Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-Reported Outcomes in Elderly Patients with Inflammatory Bowel Disease
Medication Adherence in Patients with Inflammatory Bowel Diseases within the CCFA Partners Cohort